Compare BBU & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBU | XENE |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | Bermuda | Canada |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.2B |
| IPO Year | 2015 | 2014 |
| Metric | BBU | XENE |
|---|---|---|
| Price | $30.64 | $56.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $39.40 | ★ $67.25 |
| AVG Volume (30 Days) | 25.0K | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,823.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.63 | $26.74 |
| 52 Week High | $37.75 | $62.91 |
| Indicator | BBU | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 29.79 | 66.89 |
| Support Level | $24.33 | $38.36 |
| Resistance Level | $36.93 | N/A |
| Average True Range (ATR) | 1.17 | 2.34 |
| MACD | -0.39 | 1.59 |
| Stochastic Oscillator | 0.81 | 69.75 |
Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.